Drug Profile
Melatonin
Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Anti-inflammatories; Chemoprotectants; Hormones; Radioprotectives; Sleep disorder therapies; Tryptamines
- Mechanism of Action Platelet-derived growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Hypercholesterolaemia; Inflammation; Solid tumours; Thrombocytopenia
Most Recent Events
- 10 Mar 2003 No development reported - Clinical-Phase-Unknown for Hypercholesterolaemia in USA (PO)
- 10 Mar 2003 No development reported - Clinical-Phase-Unknown for Thrombocytopenia in Italy (PO)
- 10 Mar 2003 No development reported - Phase-II for Breast cancer in Italy (PO)